Differential dose adjustments of immunosuppressants after resuming boosted versus unboosted HIV-protease inhibitors postliver transplant: Brief communication

American Journal of Transplantation

Volumn 9, Issue 10, 2009, Pages 2429-2434

  Guaraldi, G ^a   Cocchi, S ^a   Motta, A ^a   Ciaffi, S ^a   Conti, C ^a   Codeluppi, M ^a   Bonora, S ^b   Zona, S ^a   Di Benedetto, F ^a   Pinetti, D ^a   D'Avolio, A ^b   Bertolini, A ^a   Esposito, R ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

HIV; Immunosuppressants; Liver transplantation; Pharmacokinetics; Transplantation

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; CYCLOSPORIN; EMTRICITABINE; ENFUVIRTIDE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RAPAMYCIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TACROLIMUS; TENOFOVIR; ZIDOVUDINE;

ACUTE KIDNEY FAILURE; ADULT; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SUBSTITUTION; FEMALE; GLOMERULUS FILTRATION RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 70349212425     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02778.x     Document Type: Article

References (20)

1. Ragni MV, Dodson SF, Hunt SC, Bontempo FA, Fung JJ. Liver transplantation in a hemophilia patient with acquired immunodeficiency syndrome. Blood 1999 93 : 1113 1114.
2. Calabrese LH, Albrecht M, Young J et al. Successful cardiac transplantation in an HIV-1-infected patient with advanced disease. N Engl J Med 2003 348 : 2323 2328.
3. Neff GW, Bonham A, Tzakis AG et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003 9 : 239 247.
4. Ragni MV, Belle SH, Im K et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003 188 : 1412 1420.
5. Stock PG, Roland ME, Carlson L et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: A pilot safety and efficacy study. Transplantation 2003 76 : 370 375.
6. Abbott KC, Swanson SJ, Agodoa LY, Kimmel PL. Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. J Am Soc Nephrol 2004 15 : 1633 1639.
7. Kumar MS, Sierka DR, Damask AM et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int 2005 67 : 1622 1629.
8. Brinkman K, Huysmans F, Burger DM. Pharmacokinetic interaction between saquinavir and cyclosporine. Ann Intern Med 1998 129 : 914 915.
9. Jain AK, Venkataramanan R, Fridell JA et al. Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: A case report. Liver Transpl 2002 8 : 838 840.
10. Vogel M, Voigt E, Michaelis HC et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl 2004 10 : 939 944.
11. Tseng A, Nguyen ME, Cardella C, Humar A, Conly J. Probable interaction between efavirenz and cyclosporine. AIDS 2002 16 : 505 506.
12. Benet LZ, Cummins CL, Wu CY. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm 2004 277 : 3 9.
13. Frassetto LA, Browne M, Cheng A, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007 7 : 2816 2820.
14. Teicher E, Vincent I, Bonhomme-Faivre L. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clin Pharmacokinet 2007 46 : 941 952.
15. Frassetto L, Baluom M, Jacobsen W. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation 2005 80 : 13 17.
16. O'Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A. Tacrolimus versus microemulsified ciclosporin in liver transplantation: The TMC randomised controlled trial. Lancet 2002 360 : 1119 1125.
17. Pini LA, Gallesi D, Brovia D et al. Switching from HPLC/UV to MEIA for whole blood sirolimus quantitation: Comparison of methods. J Clin Lab Anal 2006 20 : 239 244.
18. Wu EY, Wilkinson JM 2nd., Naret DG et al. High-performance liquid chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasma. J Chromatogr B Biomed Sci Appl 1997 695 : 373 380.
19. Justesen US. Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy. Basic Clin Pharmacol Toxicol 2006 98 : 20 31.
20. Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003 349 : 931 940.